Company Overview

Braxia Scientific Corp. is a Canadian mental health and research company focused on developing and delivering treatments for depression, post-traumatic stress disorder (PTSD), anxiety disorders, and related neuropsychiatric conditions. The company operates in the healthcare and biotechnology sectors, with an emphasis on psychedelic-assisted therapies, ketamine treatment protocols, and clinical research tied to novel psychiatric treatments. Public disclosures and Canadian securities filings indicate that Braxia has concentrated on integrating clinical care delivery with research activities to support evidence-based mental health treatment models.

The company’s primary business activities have included operating specialty clinics, conducting clinical research, and pursuing intellectual property and treatment protocols related to ketamine-assisted therapy and psychedelic medicine. Braxia evolved from earlier business structures associated with psychedelic medicine ventures and reoriented toward a medically supervised treatment and research model under the Braxia Scientific name. Its positioning has centered on combining psychiatric expertise, clinical infrastructure, and translational research capabilities within the emerging psychedelic and mental health treatment industry.

Business Operations

Braxia Scientific has historically organized operations around mental health treatment services and clinical research activities. The company has operated through clinic-based care models and affiliated treatment centers focused on ketamine infusion therapy and psychiatric care for treatment-resistant mental health conditions. Revenue generation has primarily been tied to patient treatment services, healthcare clinic operations, and related research initiatives. Public filings also reference activities connected to treatment protocol development and clinical collaborations.

The company’s operational footprint has been concentrated mainly in Canada, particularly through clinical and research assets associated with psychiatric treatment centers. Braxia has also pursued strategic relationships with healthcare professionals, researchers, and affiliated treatment organizations involved in psychedelic medicine and neuropsychiatric care. Public disclosures reference involvement with subsidiaries and affiliated entities connected to clinic management and psychiatric research; however, some historical organizational structures and ownership arrangements have changed over time, and certain details are inconclusive based on available public sources.

Strategic Position & Investments

Braxia Scientific’s strategic direction has focused on expanding access to evidence-based mental health therapies while participating in the broader development of psychedelic-assisted medicine. The company has emphasized research into ketamine and related therapeutic modalities for depression and other psychiatric disorders. Its strategy has included integrating treatment delivery with clinical data collection and psychiatric research to support long-term commercialization and credibility within regulated healthcare markets.

The company has also pursued acquisitions and investments tied to mental health clinics and treatment infrastructure. Historical public disclosures reference acquisitions and affiliations involving psychiatric treatment clinics and healthcare operations intended to strengthen Braxia’s clinical network. Braxia has participated in the emerging psychedelic medicine sector alongside other companies exploring psilocybin-assisted therapy, ketamine-based treatment programs, and neuropsychiatric drug development. Some announced strategic initiatives and expansion plans have evolved over time, and certain outcomes remain unclear based on publicly available information.

Geographic Footprint

Braxia Scientific is headquartered in Canada, with its operations historically concentrated in the Canadian mental healthcare market. The company’s treatment and research activities have primarily focused on Canadian clinical settings and healthcare partnerships, particularly in urban markets where specialty psychiatric services are accessible.

While Braxia has participated in a sector with international investor and research interest, its direct operational presence outside Canada has been limited based on available public disclosures. The company’s visibility in public capital markets has included trading activity accessible to investors in both Canada and the United States through Canadian exchanges and U.S. over-the-counter markets.

Leadership & Governance

Braxia Scientific’s leadership has included executives and medical professionals with backgrounds in psychiatry, healthcare operations, biotechnology, and capital markets. Public company disclosures indicate that the company has emphasized physician involvement and scientific oversight as part of its governance and operating philosophy, particularly in relation to psychiatric treatment protocols and clinical research standards.

Key executives and leadership figures associated with Braxia Scientific in public filings and company disclosures have included:

• Roger McIntyre – Executive Chairman
• Dr. Roger McIntyre – Psychiatrist and mental health researcher associated with the company’s scientific direction
• Daniel Carcillo – Former business and strategic advisor associated with mental health and concussion-related initiatives
• Shawn Moniz – Former Chief Executive Officer

Leadership composition and executive appointments have changed periodically as the company evolved its business model and strategic priorities. Certain historical executive roles and timelines may vary across public disclosures, and some governance details are inconclusive based on available public sources.